Advances in Targeting KRAS G12C in Gastrointestinal Malignancies: Focus on KRAS G12C Inhibitors
Authors:
Open Access
- 1 December 2024
- journal article
- Published by Touch Medical Media, Ltd. in Oncology & Haematology
- Vol. 20 (2) , 25-33
Abstract
Rat sarcoma virus (RAS) proteins are a family of prototypical oncogenes frequently mutated in human cancers. Mutations in the RAS gene account for 19% of allKeywords
This publication has 77 references indexed in Scilit:
- 1622P D-1553 in patients with KRAS G12C mutated advanced pancreatic cancer (pca)Annals of Oncology, 2023
- 550O Safety and efficacy of D-1553 in combination with cetuximab in KRAS G12C mutated colorectal cancer (CRC): A phase II studyAnnals of Oncology, 2023
- LBA10 Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase III studyAnnals of Oncology, 2023
- 653O Glecirasib (KRAS G12C inhibitor) in combination with JAB-3312 (SHP2 inhibitor) in patients with KRAS p.G12C mutated solid tumorsAnnals of Oncology, 2023
- O-3 Characterization of KRAS mutation variants and prevalence of KRAS-G12C in gastrointestinal malignanciesAnnals of Oncology, 2021
- Targeting KRAS(G12C): From Inhibitory Mechanism to Modulation of Antitumor Effects in PatientsCell, 2020
- Current therapy of KRAS-mutant lung cancerCancer and Metastasis Reviews, 2020
- Targeting the untargetable KRAS in cancer therapyActa Pharmaceutica Sinica B, 2019
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung CarcinomaCancer Cell, 2010
- Physiological concentrations of purines and pyrimidinesMolecular and Cellular Biochemistry, 1994